Recent studies highlight the critical role of the gut microbiome in overall health, influencing everything from fear responses and mental well-being to weight regulation and autoimmune conditions like lupus and type 1 diabetes. Its impact spans both physical and psychological functions, underscoring its importance in disease prevention and management. This growing body of research continues to reveal just how deeply interconnected gut health is with nearly every aspect of our well-being.
A new study in The Journal of Immunology suggests a mother’s gut microbiome—not the child’s—may influence autism risk, based on animal research. The findings highlight a potential prenatal link between maternal gut health and neurodevelopment. While promising, further studies are needed to confirm this connection in humans.
“The microbiome can shape the developing brain in multiple ways,” said John Lukens, lead researcher and PhD candidate at the University of Virginia School of Medicine. His team’s study suggests a mother’s gut bacteria may influence her child’s neurodevelopment—potentially even autism risk—though more research is needed to confirm the link in humans.
The key may lie in interleukin-17a (IL-17a), an immune molecule already linked to autoimmune disorders like rheumatoid arthritis and psoriasis. While crucial for fighting infections—especially fungal ones—this molecule also appears to shape fetal brain development. The new research suggests it could be a critical factor in the microbiome-autism connection.
To test IL-17a’s role in autism, researchers blocked the molecule in mice. They used two groups of female mice—one genetically prone to IL-17a-driven inflammation due to their gut microbiome, and another control group without this trait.
The results showed a clear pattern: when researchers blocked IL-17a, all offspring exhibited normal neurological development. However, when left unmodified, pups from inflammation-prone mothers consistently developed autism-like symptoms, particularly affecting social behaviors and inducing repetitive actions. This striking difference strongly implicates maternal IL-17a in neurodevelopmental outcomes.
To verify the microbiome’s role, researchers performed fecal microbiota transplantation (FMT) from the inflammation-prone mice to the control group. This transfer successfully replicated the autistic-like neurodevelopmental outcomes in the control group’s offspring, demonstrating that the gut microbiome was indeed the causative factor. The transplanted mice exhibited the same behavioral abnormalities – impaired social interactions and increased repetitive behaviors – confirming the microbiome’s critical influence on neurodevelopment.
While these findings derive from animal models and require validation in human studies, they establish a compelling mechanistic link between maternal gut health and neurodevelopmental outcomes. The research provides robust preclinical evidence that maternal microbiome dysbiosis – mediated through IL-17a signaling – may contribute to autism spectrum disorder pathogenesis. This discovery opens new avenues for both diagnostic biomarkers and potential therapeutic strategies targeting the maternal-fetal interface.
The next step is confirming these findings in humans and pinpointing specific microbiome factors linked to autism,” said Lukens. “IL-17a could be just one piece of the puzzle—there are likely other key molecules involved.
